Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?
S.S. Nitecki, M.G. Sarr, and T.V. Colby Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221 1995 59 66
Resection margins in carcinoma of the head of the pancreas: Implications for radiation therapy
C.G. Willett, K. Lewandrowski, and A.L. Warshaw Resection margins in carcinoma of the head of the pancreas: Implications for radiation therapy Ann Surg 217 1993 144 148
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group
774
J.H. Klinkenbijl, J. Jeekel, and T. Sahmoud Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group Ann Surg 230 1999 776 782 774
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
Gastrointestinal Tumor Study Group
Gastrointestinal Tumor Study Group Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer Cancer 59 1987 2006 2010
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
J.P. Neoptolemos, D.D. Stocken, and H. Friess A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial
W.F. Regine, K.A. Winter, and R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial JAMA 299 2008 1019 1026
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study
B. Chauffert, F. Mornex, and F. Bonnetain Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study Ann Oncol 19 2008 1592 1599
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer
E. Ben-Josef, A.F. Shields, and U. Vaishampayan Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer Int J Radiat Oncol Biol Phys 59 2004 454 459
A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma
M.W. Brown, H. Ning, and B. Arora A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma Int J Radiat Oncol Biol Phys 65 2006 274 283
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome
M.T. Milano, S.J. Chmura, and M.C. Garofalo Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome Int J Radiat Oncol Biol Phys 59 2004 445 453
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers
S. Yovino, M. Poppe, and S. Jabbour Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers Int J Radiat Oncol Biol Phys 79 2011 158 162
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
A.C. Koong, E. Christofferson, and Q.T. Le Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 63 2005 320 323
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas
Jan 28. [Epub ahead of print]
R.A. Abrams, K.A. Winter, and W.F. Regine Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 2011 Jan 28. [Epub ahead of print]
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study
J.L. Van Laethem, P. Hammel, and F. Mornex Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study J Clin Oncol 28 2010 4450 4456
Abrams R, Regine WF, Goodman KA, et al. Consensus panel contouring atlas for the delineation of the clinical target volume in the postoperative treatment of pancreatic cancer [RTOG Web site]. April 16, 2010. Available from: http://www.rtog.org/CoreLab/ContouringAtlases/PancreasAtlas.aspx. Accessed April 21, 2011.
